IGFBP-3 is a direct target of transcriptional regulation by ΔNp63α in squamous epithelium

Cancer Research

Volumn 65, Issue 6, 2005, Pages 2314-2320

  Barbieri, Christopher E ^a   Perez, Carmen A ^a   Johnson, Kimberly N ^a   Ely, Kim A ^a   Billheimer, Dean ^a   Pietenpol, Jennifer A ^a,b  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P63; SOMATOMEDIN BINDING PROTEIN 3; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR DELTA NP63 ALPHA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BINDING SITE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; SQUAMOUS CELL CARCINOMA; SQUAMOUS EPITHELIUM; TRANSCRIPTION REGULATION;

APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; DNA-BINDING PROTEINS; EPITHELIAL CELLS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; KERATINOCYTES; PHOSPHOPROTEINS; TRANS-ACTIVATORS; TRANSCRIPTION, GENETIC; TRANSFECTION; TUMOR SUPPRESSOR PROTEINS; UP-REGULATION;

EID: 16844386318     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-3449     Document Type: Article

References (51)

1. Yang A, Kaghad M, Wang Y, et al. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 1998;2:305-16.
2. Yang A, McKeon F. P63 and P73: P53 mimics, menaces and more. Nat Rev Mol Cell Biol 2000;1:199-207.
3. Augustin M, Bamberger C, Paul D, Schmale H. Cloning and chromosomal mapping of the human p53-related KET gene to chromosome 3q27 and its murine homolog Ket to mouse chromosome 16. Mamm Genome 1998;9:899-902.
4. Osada M, Ohba M, Kawahara C, et al. Cloning and functional analysis of human p51, which structurally and functionally resembles p53. Nat Med 1998;4:839-43.
5. Chen X. The p53 family: same response, different signals? Mol Med Today 1999;5:387-92.
6. Westfall MD, Mays DJ, Sniezek JC, Pietenpol JA. The ΔNp63α phosphoprotein binds the p21 and 14-3-3s promoters in vivo and has transcriptional repressor activity that is reduced by Hay-Wells syndrome-derived mutations. Mol Cell Biol 2003;23:2264-76.
7. Flores ER, Tsai KY, Crowley D, et al. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 2002;416:560-4.
8. Di Como CJ, Urist MJ, Babayan I, et al. p63 expression profiles in human normal and tumor tissues. Clin Cancer Res 2002;8:494-501.
9. Dellavalle RP, Egbert TB, Marchbank A, et al. CUSP/p63 expression in rat and human tissues. J Dermatol Sci 2001;27:82-7.
10. Nylander K, Coates PJ, Hall PA. Characterization of the expression pattern of p63α and ΔNp63α in benign and malignant oral epithelial lesions. Int J Cancer 2000;87:368-72.
11. Bamberger C, Schmale H. Identification and tissue distribution of novel KET/p63 splice variants. FEBS Lett 2001;501:121-6.
12. Lee H, Kimelman D. A dominant-negative form of p63 is required for epidermal proliferation in zebrafish. Dev Cell 2002;2:607-16.
13. Bakkers J, Hild M, Kramer C, et al. Zebrafish ΔNp63 is a direct target of Bmp signaling and encodes a transcriptional repressor blocking neural specification in the ventral ectoderm. Dev Cell 2002;2:617-27.
14. Pellegrini G, Dellambra E, Golisano O, et al. p63 identifies keratinocyte stem cells. Proc Natl Acad Sci U S A 2001;98:3156-61.
15. Parsa R, Yang A, McKeon F, Green H. Association of p63 with proliferative potential in normal and neoplastic human keratinocytes. J Invest Dermatol 1999;113:1099-105.
16. Donehower LA, Harvey M, Slagle BL, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992;356:215-21.
17. Yang A, Schweitzer R, Sun D, et al. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 1999;398:714-8.
18. Mills AA, Zheng BH, Wang XJ, et al. p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 1999;398:708-13.
19. Hibi K, Trink B, Patturajan M, et al. AIS is an oncogene amplified in squamous cell carcinoma. Proc Natl Acad Sci U S A 2000;97:5462-7.
20. Choi HR, Batsakis JG, Zhan F, et al. Differential expression of p53 gene family members p63 and p73 in head and neck squamous tumorigenesis. Hum Pathol 2002;33:158-64.
21. Park BJ, Lee SJ, Kim JI, et al. Frequent alteration of p63 expression in human primary bladder carcinomas. Cancer Res 2000;60:3370-4.
22. Hu H, Xia SH, Li AD, et al. Elevated expression of p63 protein in human esophageal squamous cell carcinomas. Int J Cancer 2002;102:580-3.
23. Liefer KM, Koster MI, Wang XJ, et al. Down-regulation of p63 is required for epidermal UV-B-induced apoptosis. Cancer Res 2000;60:4016-20.
24. Hochscheid R, Jaques G, Wegmann B. Transfection of human insulin-like growth factor-binding protein 3 gene inhibits cell growth and tumorigenicity: a cell culture model for lung cancer. J Endocrinol 2000;166:553-63.
25. Devi GR, Sprenger CC, Plymate SR, Rosenfeld RG. Insulin-like growth factor binding protein-3 induces early apoptosis in malignant prostate cancer cells and inhibits tumor formation in vivo. Prostate 2002;51:141-52.
26. Kim HS, Ingermann AH, Tsubaki J, et al. Insulin-like growth factor-binding protein 3 induces caspase-dependent apoptosis through a death receptor-mediated pathway in MCF-7 human breast cancer cells. Cancer Res 2004;64:2229-37.
27. Hollowood AD, Lai T, Perks CM, et al. IGFBP-3 prolongs the p53 response and enhances apoptosis following UV irradiation. Int J Cancer 2000;88:336-41.
28. Longobardi L, Torello M, Buckway C, et al. A novel insulin-like growth factor (IGF)-independent role for IGF binding protein-3 in mesenchymal chondroprogenitor cell apoptosis. Endocrinology 2003;144:1695-702.
29. Buckbinder L, Talbott R, Velasco-Miguel S, et al. Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 1995;377:646-9.
30. McCurrach ME, Connor TM, Knudson CM, et al. bax-deficiency promotes drug resistance and oncogenic transformation by attenuating p53-dependent apoptosis. Proc Natl Acad Sci U S A 1997;94:2345-9.
31. Shibue T, Takeda K, Oda E, et al. Integral role of Noxa in p53-mediated apoptotic response. Genes Dev 2003;17:2233-8.
32. Villunger A, Michalak EM, Coultas L, et al. p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science 2003;302:1036-8.
33. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 2002;296:550-3.
34. Barbieri CE, Barton CE, Pietenpol JA. ΔNp63α expression is regulated by the phosphoinositide 3-kinase pathway. J Biol Chem 2003;278:51408-14.
35. Flatt PM, Price JO, Shaw A, Pietenpol JA. Differential cell cycle checkpoint response in normal human keratinocytes and fibroblasts. Cell Growth Differ 1998;9:535-43.
36. Matheny KE, Barbieri CE, Sniezek JC, et al. Inhibition of epidermal growth factor receptor signaling decreases p63 expression in head and neck squamous carcinoma cells. Laryngoscope 2003;113:936-9.
37. Senoo M, Matsumura Y, Habu S. Identification of a novel retrovirus long terminal repeat (LTR) that is targeted by p51A (TAp63γ) and selective dominant-negative activity of p73L (ΔNp63α) toward p53-responsive promoter activities. Biochem Biophys Res Commun 2001;286:628-34.
38. Harmes DC, Bresnick E, Lubin EA, et al. Positive and negative regulation of ΔN-p63 promoter activity by p53 and ΔN-p63-α contributes to differential regulation of p53 target genes. Oncogene 2003;22:7607-16.
39. Szak ST, Mays D. Pietenpol JA. Kinetics of p53 binding to promoter sites in vivo. Mol Cell Biol 2001;21:3375-86.
40. Yamaguchi K, Wu L, Caballero O, et al. Frequent gain of the p40/p51/p63 gene locus in primary head and neck squamous cell carcinoma. Int J Cancer 2000;86:684-9.
41. Ratovitski EA, Patturajan M, Hibi K, et al. p53 associates with and targets ΔNp63 into a protein degradation pathway. Proc Natl Acad Sci U S A 2001;98:1817-22.
42. Tanière P, Martel-Planche G, Saurin JC, et al. TP53 mutations, amplification of P63 and expression of cell cycle proteins in squamous cell carcinoma of the oesophagus from a low incidence area in Western Europe. Br J Cancer 2001;85:721-6.
43. Patturajan M, Nomoto S, Sommer M, et al. ΔNp63 induces β-catenin nuclear accumulation and signaling. Cancer Cell 2002;1:369-79.
44. Wu G, Nomoto S, Hoque MO, et al. ΔNp63α and TAp63α Regulate transcription of genes with distinct biological functions in cancer and development. Cancer Res 2003;63:2351-7.
45. Butt AJ, Williams AC. IGFBP-3 and apoptosis: a license to kill? Apoptosis 2001;6:199-205.
46. Katsaros D, Yu H, Levesque MA, et al. IGFBP-3 in epithelial ovarian carcinoma and its association with clinico-pathological features and patient survival. Eur J Cancer 2001;37:478-85.
47. Chang YS. Kong G, Sun S, et al. Clinical significance of insulin-like growth factor-binding protein-3 expression in stage I non-small cell lung cancer. Clin Cancer Res 2002;8:3796-802.
48. Dietz S, Rother K, Bamberger C, et al. Differential regulation of transcription and induction of programmed cell death by human p53-family members p63 and p73. FEBS Lett 2002;525:93-9.
49. Dohn M, Zhang SZ, Chen XB. p63a and ΔNp63a can induce cell cycle arrest and apoptosis and differentially regulate p53 target genes. Oncogene 2001;20:3193-205.
50. King KE, Ponnamperuma RM, Yamashita T, et al. deltaNp63α functions as both a positive and a negative transcriptional regulator and blocks in vitro differentiation of murine keratinocytes. Oncogene 2003;22:3635-44.
51. Wischhusen J, Melino G, Weller M. p53 and its family members - reporter genes may not see the difference. Cell Death Differ 2004;11:1150-2.